Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 6/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 6/20 | 0.48 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 2/20 | 0.42 |
| ▸ | QPCT | Q16769 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL283762 | 0.86 | HTR2C (0.50) | CHRM1CHRM3MEN1KMT2ACHRM2 | |
| SCHEMBL8901933 | 0.72 | NOS1 (0.54) | — | |
| SCHEMBL14136432 | 0.71 | MEN1 (0.50) | MEN1KMT2AMAPK1DRD2 | |
| SCHEMBL16293191 | 0.71 | DRD4 (0.50) | MEN1KMT2A | |
| SCHEMBL2182332 | 0.70 | MAOA (0.46) | MEN1KMT2APKMDRD2 | |
| SCHEMBL824153 | 0.70 | DRD2 (0.69) | MEN1KMT2ADRD2 | |
| SCHEMBL6710920 | 0.70 | ALDH1A1 (0.56) | CHRM1MEN1KMT2ACHRM2NPC1 | |
| SCHEMBL24123872 | 0.69 | QDPR (0.50) | MEN1KMT2AACHEDRD2 | |
| SCHEMBL14174295 | 0.68 | TSPO (0.59) | MEN1KMT2ANPC1RAB9AMAPK1 | |
| SCHEMBL22062939 | 0.68 | MEN1 (0.51) | MEN1KMT2ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2428508-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | Astellas Pharma Inc. (JP) | 2012-03-14 | — | — | EP | disclosed |
| US-20120040968-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | WATERS TECHNOLOGIES CORPORATION (US) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040968-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | EML4, ALK, ERBB4 | CHRM1 3675/4885CHRM3 3297/4885CHRM5 3377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.